Biofrontera Inc. BFRI
Set alert
At close · Oct 30
After hours · Oct 30, 6:50 PM ET
- YTD
- +53.14%
- 1 year
- -18.42%
- Open
- 0.94
- Prev close
- 0.9315
- Mkt cap
- 12.96M
- Vol
- 302.43K
- Avg vol
- 508.18K
- EPS
- -0.43
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.8487
- High
- 0.94
- Forward P/E
- -1.17
- Beta
- 0.51
- Short ratio
- 0.08
- Inst. own
- 20.68%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 0.93324
- 200-d avg
- 1.17
- 1y target
- 11.50
5D chart
Signals (124)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 11:25 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:00 AM | 1 day ago |
| RSI: Oversold | Oct 30, 11:00 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:55 AM | 1 day ago |
| RSI: Oversold | Oct 30, 10:15 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:55 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:40 AM | 1 day ago |
| SMA: Bullish | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bullish | Oct 30, 9:30 AM | 1 day ago |
| MACD: Sell Signal | Oct 29, 4:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:55 PM | 2 days ago |
| RSI: Overbought | Oct 29, 3:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:10 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 2:25 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:55 PM | 2 days ago |
| RSI: Overbought | Oct 29, 1:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:40 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:00 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:50 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 12:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 12:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:10 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 11:50 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 11:20 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 11:15 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 11:05 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:55 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:40 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:55 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 9:55 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:55 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:50 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 9:45 AM | 2 days ago |
| MACD: Buy Signal | Oct 28, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 3 days ago |
| RSI: Overbought | Oct 28, 2:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 12:45 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 11:55 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:45 AM | 3 days ago |
| RSI: Overbought | Oct 28, 11:20 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 11:10 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:00 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:20 AM | 3 days ago |
| RSI: Oversold | Oct 28, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 28, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 27, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 1:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:15 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:15 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:50 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 5 days ago |
| RSI: Oversold | Oct 26, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:20 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:00 AM | 5 days ago |
News
-
3 weeks ago benzinga.com
Biofrontera Refiles Supplemental New Drug Application For Ameluz Topical Gel To FDA To Treat Actinic Keratoses
Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Flyte Aviation, Inc. Common Stock (AMEX:VJET) stock moved upwards by 34.0% to $2.17 during Monday's after-market session. Option Care Health (NASDAQ:OPCH) shares rose 20.92% to $28.26. The…
1 month ago benzinga.com
Transcript: Biofrontera Q2 2026 Earnings Conference Call
On Thursday, Biofrontera (NASDAQ:BFRI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…
-
1 month ago benzinga.com
Biofrontera Receives FDA Supplemental New Drug Application Approval For Its Ameluz Topical Gel, 10%, In Combination With Photodynamic Therapy Using The BF-RhodoLED Lamp Series For The Treatment Of Superficial Basal Cell Carcinoma In Adults
With this approval, Ameluz becomes the first and only PDT drug approved by the FDA for the treatment of a skin cancer, and the only topical PDT in the United States indicated to treat both a…
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-market session. The company's market cap stands at $3.5 million. Biodexa Pharmaceuticals (NASDAQ:BDRX)…
-
2 months ago benzinga.com
Biofrontera Q2 EPS $(0.05) Misses $(0.04) Estimate, Sales $12.003M Beat $10.500M Estimate
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 91.23 percent increase over losses of $(0.57)…
5 months ago benzinga.com
This Hanover Insurance Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Wall Street analysts changed ratings on top names. Check our analyst ratings page for full updates. THG, BFRI covered.
5 months ago benzinga.com
This Stubhub Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday
Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. See what other analysts think of these stocks.
-
5 months ago benzinga.com
Benchmark Downgrades Biofrontera to Speculative Buy, Maintains Price Target to $3
Benchmark analyst Bruce D. Jackson downgrades Biofrontera (NASDAQ:BFRI) from Buy to Speculative Buy and maintains the price target from $3 to $3.
-
5 months ago benzinga.com
Transcript: Biofrontera Q1 2026 Earnings Conference Call
Transcript: Biofrontera Q1 2026 Earnings Conference Call
-
5 months ago benzinga.com
Biofrontera Q1 EPS $(0.41) Misses $(0.12) Estimate, Sales $10.084M Miss $10.250M Estimate
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.12) by 272.73 percent. This is a 12.77 percent increase over losses of…
-
7 months ago benzinga.com
Biofrontera Q4 EPS $0.48 Beats $0.20 Estimate, Sales $17.100M Beat $16.146M Estimate
Biofrontera (NASDAQ:BFRI) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.20 by 146.15 percent. This is a 352.63 percent increase over losses of $(0.19)…
-
7 months ago benzinga.com
Earnings Scheduled For March 19, 2026
Earnings Scheduled For March 19, 2026
-
8 months ago benzinga.com
Biofrontera Announces US Patent Trial And Appeal Board Final Written Decision Finding All Challenged Claims Of Sun Pharma's '028 Patent To Be Unpatentable
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy ("PDT"), today announced that on February 23, 2026, the U.S.…
-
8 months ago benzinga.com
Biofrontera's Supplemental New Drug Application For Ameluz Accepted By FDA
Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (PDT), today announced that…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
8 months ago benzinga.com
Biofrontera Announces Results From 172 Participants In Its Phase 3 Cliical Study Of Ameluz Photodynamic Therapy To Treat Actinic Keratoses
Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced…
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
9 months ago benzinga.com
Biofrontera Expects Q4 Revenue Between $17M - $17.5M, FY25 Revenue Between $41.5M - $42M
Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for…
-
9 months ago benzinga.com
Biofrontera Locks Databases For Treatment Phase Of Phase 3 Clinical Trial Of Ameluz PDT, Phase 2 Clinical Trial To Treat Moderate To Severe Acne Vulgaris
Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the…
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
10 months ago benzinga.com
Why Baidu Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Why Baidu Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
10 months ago benzinga.com
Biofrontera Transfers Of Ameluz, RhodoLED New Drug Applications, Investigational New Drug Applications; Completes Requirements For Transfer Of All U.S., Some Global Intellectual Property Associated With Ameluz And RhodoLED
Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced the completion of the transfer of the FDA…
-
11 months ago benzinga.com
Biofrontera Completes Final Patient Visit In Phase 1 Pharmacokinetic Study Of Ameluz Gel, 10%, For Treatment Of Mild To Moderate Actinic Keratoses On Neck, Trunk And Extremities
Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz® over treatment area of 240 cm2Completion of this study marks a key milestone…
-
11 months ago benzinga.com
Biofrontera Files sNDA For Ameluz-PDT To Treat sBCC After Phase 3 Trial Achieves 65.5% Complete Clearance Of Main Target Lesions; Primary And Key Secondary Endpoints Met With High Statistical Significance With Favorable One-Year Recurrence and Aesthetic Outcomes
sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to…
-
11 months ago benzinga.com
Biofrontera Q3 EPS $(0.62) Misses $(0.58) Estimate, Sales $6.988M Miss $7.000M Estimate
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.58) by 6.9 percent. This is a 36.73 percent increase over losses of $(0.98)…
-
11 months ago benzinga.com
Earnings Scheduled For November 12, 2025
Earnings Scheduled For November 12, 2025
-
11 months ago benzinga.com
Biofrontera Announces The Sale Of Its U.S. License For Xepi Cream To Pelthos Therapeutics. The Company Received $3M Upfront, Will Get $1M Upon Product Availability, And May Earn Up To $6M In Milestone Payments Tied To Future U.S. Sales Performance.
Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further…
11 months ago benzinga.com
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch
Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings.
-
1 year ago benzinga.com
Biofrontera Completes Treatment Phase In Phase 3 Trial Of Ameluz For Actinic Keratosis On Body; Supplemental New Drug Application Planned For Submission In Q2 2026
All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in October 2024 for use of up to 3 tubes of Ameluz® per treatmentStudy…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
Biofrontera Completes Final Patient Visit In Phase 2b Acne Trial, Top-Line Results Expected Q1 2026; Plans FDA Discussion For Phase 3 In Q3
Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansionMore…
-
1 year ago benzinga.com
Biofrontera Q2 EPS $(0.57) Misses $(0.42) Estimate, Sales $9.03M Beat $8.30M Estimate
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.42) by 35.71 percent. This is a 1040 percent decrease over losses of…
-
1 year ago benzinga.com
Earnings Scheduled For August 13, 2025
Earnings Scheduled For August 13, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
1 year ago benzinga.com
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
Earnings Scheduled For November 13, 2024
Earnings Scheduled For November 13, 2024
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session